CIK细胞对化疗后晚期非小细胞肺癌的临床疗效评估

目的探观察化疗后晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者给予细胞因子诱导的杀伤细胞（cytokine-induced killer cells, CIK）治疗后免疫功能及生活质量变化，探讨CIK细胞治疗晚期肺癌的近期疗效及安全性。方法收集化疗后晚期NSCLC患者61例，选取同期最佳支持治疗的61例化疗后晚期NSCLC患者作为对照组，比较CIK细胞治疗后外周血T淋巴细胞亚群、KPS评分、近期疗效及评估安全性。结果CIK治疗组患者外周血CD3+、CD3+/CD4+细胞比率较治疗前显著上升（P < 0.05），对照组T淋巴细胞亚群没有变化。CIK细胞治疗后患者KPS评分为67.27±8.94，较治疗前显著提高（P < 0.05）。CIK治疗组疾病控制率为85.25%，显著高于对照组的59.01%（P < 0.05）。CIK治疗组中出现4例一过性发热和3例皮疹患者，未见其他明显毒副作用。结论CIK治疗化疗后晚期非小细胞肺癌患者，改善免疫功能及生活质量，提高近期疾病控制率，安全性好。 

The Study of Cytokine-induced Killer Cells Treating Patients with Advanced Non-small Cell Lung Cancer after Chemotherapy

ObjectiveTo investigate the changes of immunity and life quality after the treatment of cytokine induced-killer cells (CIKs) for patients with advanced NSCLC after chemotherapy, and to assess the effectiveness and safety of CIKs treatment.MethodSixty-one patients with advanced NSCLC after chemotherapy treated with CIKs were enrolled as CIKs group, and another sixty-one post-chemotherapy patients of advanced NSCLC treated with optimal supportive care during the same period were enrolled as control group. Before and after CIK cells being transfused back, the changes of immune system including subsets of T cells, quality of life (Karnofsky score), therapeutic effects and side effects were compared between the two groups.ResultCompared with before CIK cells therapy, the ratios of CD3+and CD3+/CD4+T cells significantly increased (P < 0.05), while there was no significant change in the control group. KPS score significantly increased in the CIKs group, which was 67.27±8.94(P < 0.05). The disease control rate (DCR) were 85.25% in the CIKs group, which was significantly higher than those in the control group (59.01%)(P < 0.05). The major adverse events were transient fever and skin rash, and no other side effect was observed.ConclusionCIK cells treatment is safe and effective for advanced NSCLC patients. It can improve the immune imbalance, DCR and quality of life of the patients.